Importantly, as found with our melanoma syngeneic tumorigenesis studies, Bmal1 loss diminished tumorigenicity in transgenic mouse MLL-AF4-driven leukemia53, SOS-driven squamous cell skin carcinoma54, and loss of BMAL1 or CLOCK diminished human glioblastoma tumorigenesis in orthotopic mouse models55,56. The gene discussed is KMT2A; the disease is glioblastoma.